Nature Search

Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial

James W Murrough
Katherine E Burdick
Dan V Iosifescu
Research06 Nov 2014
Neuropsychopharmacology

Volume: 40, P: 1084-1090
Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial

Sara Costi
Laili Soleimani
James W. Murrough
Research11 Mar 2019
Neuropsychopharmacology

Volume: 44, P: 1812-1819
Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant

Samuel T. Wilkinson
Cristan Farmer
Carlos A. Zarate Jr.
Research17 Jan 2019
Neuropsychopharmacology

Volume: 44, P: 1233-1238
Ketamine Treatment and Global Brain Connectivity in Major Depression

Chadi G Abdallah
Lynnette A Averill
James W Murrough
Research08 Sept 2016
Neuropsychopharmacology

Volume: 42, P: 1210-1219
Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence

Agnes Norbury
Sarah B. Rutter
Adriana Feder
Research31 Jul 2021
Neuropsychopharmacology

Volume: 46, P: 2266-2277
Effects of KCNQ potassium channel modulation on ventral tegmental area activity and connectivity in individuals with depression and anhedonia

Laurel S. Morris
Sara Costi
James W. Murrough
Research25 Mar 2025
Molecular Psychiatry

Volume: 30, P: 3686-3694
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

Maurizio Fava
Marlene P. Freeman
George I. Papakostas
Research03 Oct 2018
Molecular Psychiatry

Volume: 25, P: 1592-1603
Targeting glutamate signalling in depression: progress and prospects

Changes in glutamate signalling have been implicated in major depression, and ketamine, which was recently found to act as a rapid-acting antidepressant, affects glutamate signalling in several ways. Murrough and colleagues give an overview of the development of glutamate-signalling modulators for depression and examine studies on the mechanisms of these agents.

James W. Murrough
Chadi G. Abdallah
Sanjay J. Mathew
Reviews17 Mar 2017
Nature Reviews Drug Discovery

Volume: 16, P: 472-486
Cracking the moody brain: Lifting the mood with ketamine

James W Murrough
Dennis S Charney
Comments & Opinion06 Dec 2010
Nature Medicine

Volume: 16, P: 1384-1385
Altered hippocampus and amygdala subregion connectome hierarchy in major depressive disorder

Yael Jacob
Laurel S. Morris
James W. Murrough
ResearchOpen Access19 May 2022
Translational Psychiatry

Volume: 12, P: 1-9
Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedonia

Sara Costi
Laurel S. Morris
James W. Murrough
ResearchOpen Access05 Nov 2021
Translational Psychiatry

Volume: 11, P: 1-8
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators

Rebecca B. Price
Nicholas Kissel
Meredith L. Wallace
ResearchOpen Access07 Sept 2022
Molecular Psychiatry

Volume: 27, P: 5096-5112
Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression

Flurin Cathomas
Laura Bevilacqua
James W. Murrough
ResearchOpen Access10 Jan 2022
Translational Psychiatry

Volume: 12, P: 1-9
Circulating myeloid-derived MMP8 in stress susceptibility and depression

Serum MMP8 is increased in stress-susceptible mice following chronic stress and leads to brain structure and behavioural changes in mice.

Flurin Cathomas
Hsiao-Yun Lin
Scott J. Russo
ResearchOpen Access07 Feb 2024
Nature

Volume: 626, P: 1108-1115
Digital measures of activity and motivation impact depression and anxiety in the real world

Jacqueline M. Beltrán
Yael Jacob
Laurel S. Morris
ResearchOpen Access10 May 2025
npj Digital Medicine

Volume: 8, P: 1-15
Ultra-high field MRI reveals mood-related circuit disturbances in depression: a comparison between 3-Tesla and 7-Tesla

Laurel S. Morris
Prantik Kundu
James W. Murrough
ResearchOpen Access15 Feb 2019
Translational Psychiatry

Volume: 9, P: 1-11
KCNQ channel openers reverse depressive symptoms via an active resilience mechanism

Potassium channels in the ventral tegmental area are known to regulate resilience against stress-induced depression. Here, the authors show over expression of KCNQ3 channels in VTA dopaminergic neurons or treatment with KCNQ channel openers normalizes depressive behaviours in mouse models.

Allyson K. Friedman
Barbara Juarez
Ming-Hu Han
ResearchOpen Access24 May 2016
Nature Communications

Volume: 7, P: 1-7
A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia

A phase 2 proof-of-mechanism trial shows that a κ-opioid receptor antagonist improves reward-related functioning in the brain and a clinical measure of anhedonia in patients with mood and anxiety disorders, serving as a model for implementing the ‘fast-fail’ approach to psychiatric treatment development.

Andrew D. Krystal
Diego A. Pizzagalli
William Z. Potter
Research30 Mar 2020
Nature Medicine

Volume: 26, P: 760-768
The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development

Andrew D. Krystal
Diego A. Pizzagalli
William Potter
Correspondence28 Dec 2018
Nature Reviews Drug Discovery

Volume: 18, P: 82-84
Impact of Tryptophan Depletion on Executive System Function during Menopause is Moderated by Childhood Adversity

Sheila Shanmugan
James Loughead
C Neill Epperson
Research21 Mar 2017
Neuropsychopharmacology

Volume: 42, P: 2398-2406
A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression

Brian M. Iacoviello
James W. Murrough
Dennis S. Charney
ResearchOpen Access06 Jun 2018
npj Digital Medicine

Volume: 1, P: 1-7
Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder

Aaron Tan
Sara Costi
James W. Murrough
Research01 Nov 2018
Molecular Psychiatry

Volume: 25, P: 1323-1333
Ketamine normalizes subgenual cingulate cortex hyper-activity in depression

Laurel S. Morris
Sara Costi
James W. Murrough
Research02 Jan 2020
Neuropsychopharmacology

Volume: 45, P: 975-981
Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome

D D Kiraly
S R Horn
J W Murrough
ResearchOpen Access21 Mar 2017
Translational Psychiatry

Volume: 7, P: e1065
Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)

Diego A. Pizzagalli
Moria Smoski
Andrew D. Krystal
Amendments and Corrections13 Aug 2021
Neuropsychopharmacology

Volume: 46, P: 2224
Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance

Carla Nasca
Josh Dobbin
Natalie Rasgon
Research15 Jun 2020
Molecular Psychiatry

Volume: 26, P: 5140-5149
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

Maurizio Fava
Marlene P. Freeman
George I. Papakostas
Amendments and Corrections07 Jan 2019
Molecular Psychiatry

Volume: 25, P: 1604
Correction: Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression

Wei Guo
Rodrigo Machado-Vieira
Yin Yao Shugart
Amendments and CorrectionsOpen Access05 Mar 2019
Translational Psychiatry

Volume: 9, P: 1
Neurobiology of resilience

The authors review our understanding of the biological basis of resilience to stress. The review examines findings from both humans and animals and also discusses how this knowledge can help guide treatment for stress-related disorders.

Scott J Russo
James W Murrough
Eric J Nestler
Reviews14 Oct 2012
Nature Neuroscience

Volume: 15, P: 1475-1484
Blood miR-144-3p: a novel diagnostic and therapeutic tool for depression

Yentl Y. van der Zee
Lars M. T. Eijssen
Orna Issler
Research28 Jul 2022
Molecular Psychiatry

Volume: 27, P: 4536-4549
Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)

Diego A. Pizzagalli
Moria Smoski
Andrew D. Krystal
Research16 Jun 2020
Neuropsychopharmacology

Volume: 45, P: 1656-1663
High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions

Emily R. Stern
Rebbia Shahab
Wayne K. Goodman
Research08 Aug 2018
Neuropsychopharmacology

Volume: 44, P: 390-398
Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression

Wei Guo
Rodrigo Machado-Vieira
Yin Yao Shugart
ResearchOpen Access14 Dec 2018
Translational Psychiatry

Volume: 8, P: 1-8
The genetics of severe depression

Clio E. Franklin
Eric Achtyes
James B. Potash
Reviews15 Oct 2024
Molecular Psychiatry

Volume: 30, P: 1117-1126
Cerebellar Morphology and the Effects of Stimulant Medications in Youths with Attention Deficit-Hyperactivity Disorder

Iliyan Ivanov
James W Murrough
Bradley S Peterson
Research27 Sept 2013
Neuropsychopharmacology

Volume: 39, P: 718-726
Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder

J W Murrough
K A Collins
D V Iosifescu
ResearchOpen Access17 Feb 2015
Translational Psychiatry

Volume: 5, P: e509

Search

Filter By:

Search

Quick links